PROJECT SUMMARY
The Human Immunodeficiency Virus manipulates host cellular processes to promote synthesis of viral
components, which must be appropriately localized to subcellular domains for viral budding and release. In
addition to the structural Gag, Pol and Env polyproteins common to all retroviruses, HIV-1 encodes four
“accessory” proteins: Vpu, Nef, Vif and Vpr, which function to promote evasion of host adaptive and innate
immune responses. These viral accessory proteins co-opt host degradative and protein-trafficking processes
by functioning as molecular adaptors that form ternary complexes with targeted host factors, including the
intrinsic cellular immunity provided by host “restriction factors”, and components of the host trafficking
machinery. Elucidation of the mechanisms by which host and viral proteins can promote or inhibit infection may
lead to the identification of targets for therapeutic intervention.
We have recently identified a novel HIV-1 cofactor, ESCRT-associated protein, PTPN23 (HD-PTP), which
appears to function as a cofactor for Vpu activities. Transient knockdown of PTPN23 prevented Vpu-mediated
degradation of BST-2 and inhibited virus release. Interestingly, PTPN23 is not only for required for BST-2
degradation, but also for surface downregulation of CD4. Furthermore, our previous (unpublished) studies
support a role for clathrin and clathrin adaptor AP-2 in Vpu-mediated surface downregulation of CD4. We
hypothesize that Vpu-mediated antagonism of CD4 is mediated at least in part by endocytosis and lysosomal
degradation rather than exclusively by ERAD-like mechanisms.
Here, we propose to determine whether PTPN23 acts as a cofactor for Vpu-mediated degradation of CD4, and
elucidate the molecular mechanisms by which Vpu interacts with PTPN23. We will also validate PTPN23 as a
cofactor for Vpu activities in primary T-cells to demonstrate applicability in a viral infection setting. We will
further define additional components of the ESCRT pathway necessary for surface downregulation and/or
degradation CD4. Elucidating the molecular interactions between Vpu and ESCRT-associated proteins will
define targets for therapeutic intervention; by inhibiting Vpu's anti-immune activities we will sensitize infected
cells to detection and immune clearance.